Karimpour Fatemeh, Hooshiar Mohammad Hosseini, Abbasnejad Shima, Abdi Kimia, Jalili Arsalan, Khanmirzaei Amir, Tutunchi Sara, Javanmard Amir-Reza, Hajiesmaeili Mohammadreza, Ghaderian Sayyed Mohammad Hossein
Cancer Research Center, Health Research institute, Babol University of Medical Sciences, Babol, Iran.
Department of Periodontics, School of Dentistry, Tehran University of Medical Sciences, Tehran, Iran.
J Cell Mol Med. 2025 Aug;29(15):e70623. doi: 10.1111/jcmm.70623.
Astrocytomas are aggressive brain tumours with limited treatment options, making the identification of novel therapeutic targets crucial. Long noncoding RNAs (lncRNAs) have emerged as key regulators of gene expression and have been implicated in various cancers, including astrocytoma. LINC01614 is a lncRNA that has been found to be upregulated in astrocytoma, suggesting its potential role in tumour progression. In this study, we investigated the functional role of LINC01614 in astrocytoma and its interaction with miR-128, a known regulator of the RAS/Map kinase signalling pathway. Through in vitro experimental assays, we demonstrated that LINC01614 upregulation promotes astrocytoma cell proliferation and invasion, potentially through the sponging of miR-128. Furthermore, in silico analysis revealed potential binding sites of miR-128 within the RAS/Map kinase signalling pathway, suggesting a regulatory role for miR-128 in this pathway. Our findings provide novel insights into the molecular mechanisms underlying astrocytoma progression and highlight the potential of LINC01614 as a therapeutic target. Targeting LINC01614 or modulating miR-128 expression may offer new therapeutic strategies for astrocytoma treatment. Additionally, our in silico analysis provides a foundation for further exploration of the regulatory network involving LINC01614, miR-128 and the RAS/Map kinase signalling pathway. Overall, this study sheds light on the intricate regulatory network in astrocytoma and presents promising avenues for the development of targeted therapies for this devastating disease.
星形细胞瘤是侵袭性脑肿瘤，治疗选择有限，因此确定新的治疗靶点至关重要。长链非编码RNA（lncRNA）已成为基因表达的关键调节因子，并与包括星形细胞瘤在内的多种癌症有关。LINC01614是一种lncRNA，已发现在星形细胞瘤中上调，表明其在肿瘤进展中的潜在作用。在本研究中，我们研究了LINC01614在星形细胞瘤中的功能作用及其与miR-128的相互作用，miR-128是RAS/丝裂原活化蛋白激酶信号通路的已知调节因子。通过体外实验分析，我们证明LINC01614的上调促进星形细胞瘤细胞的增殖和侵袭，可能是通过miR-128的海绵作用。此外，计算机分析揭示了miR-128在RAS/丝裂原活化蛋白激酶信号通路中的潜在结合位点，表明miR-128在该通路中具有调节作用。我们的研究结果为星形细胞瘤进展的分子机制提供了新的见解，并突出了LINC01614作为治疗靶点的潜力。靶向LINC01614或调节miR-128的表达可能为星形细胞瘤治疗提供新的治疗策略。此外，我们的计算机分析为进一步探索涉及LINC01614、miR-128和RAS/丝裂原活化蛋白激酶信号通路的调控网络奠定了基础。总体而言，本研究揭示了星形细胞瘤中复杂的调控网络，并为这种毁灭性疾病的靶向治疗开发提供了有希望的途径。
